



MOST COST-EFFECTIVE BPH TREATMENT OPTION

COST-EFFECTIVENESS OF 5 BPH THERAPIES AT 2 YEARS POST-TREATMENT⁹

- Economic analysis conducted comparing combo drug therapy (Combo Rx), Rezūm, UroLift[®], GreenLight[®] and TURP
- GreenLight and TURP provide slightly greater relief but cost twice as much as Rezūm
- Combo Rx least effective; Combo Rx (Branded) most expensive
- UroLift similar in effectiveness to Rezūm but costs more than twice as much as Rezūm



Rezūm is the most cost-effective BPH treatment option available.



REFERENCES

- Data on file.
 - Roehrborn CG, Gange SN, Gittelman MC, et al. Convective thermal therapy: Durable 2-year results of randomized controlled and prospective crossover studies for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. *J Urol*. 2017 Jun;197(6):1507-16.
 - Ku JH, Ko DW, Cho JY, et al. Correlation between prostatic urethral angle and bladder outlet obstruction index in patients with lower urinary tract symptoms. *Urology*. 2010 Jun;75(6):1467-71.
 - McVary KT, Roehrborn CG. Three-year outcomes of the prospective, randomized controlled Rezūm system study: Convective radiofrequency thermal therapy for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. *Urology*. 2018 Jan;111:1-9.
 - Bouza C, López T, Magro A, et al. Systematic review and meta-analysis of transurethral needle ablation in symptomatic benign prostatic hyperplasia. *BMC Urol*. 2006 Jun;6:14.
 - Mynderse LA, Roehrborn CG, Partin AW, et al. Results of a 5-year multicenter trial of a new generation cooled high energy transurethral microwave thermal therapy catheter for benign prostatic hyperplasia. *J Urol*. 2011 May;185(5):1804-10.
 - Roehrborn CG, Rukstalis DB, Barkin J, et al. Three year results of the prostatic urethral L.I.F.T. study. *Can J Urol*. 2015 Jun;22(3):7772-82.
 - Darson MF, Alexander EE, Schiffman ZJ, et al. Procedural techniques and multicenter postmarket experience using minimally invasive convective radiofrequency thermal therapy with Rezūm System for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. *Res Rep Urol*. 2017 Aug 21;9:159-68.
 - Ulchaker JC, Martinson M. Cost-effectiveness analysis of six therapies for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. *Clinicoecon Outcomes Res*. 2018;10:29-43.
- UroLift is a registered trademark of NeoTract, Inc. GreenLight is a registered trademark of Boston Scientific Corporation or its affiliates.



888-319-9691 | www.rezum.com
info@rezum.com

©2018 NxThera, Inc. All rights reserved. Rezūm is a registered trademark of NxThera, Inc.

3717-005 Rev B (01/18)

A DURABLE AND COST-EFFECTIVE BPH TREATMENT OPTION

CONTRIBUTIONS BY
KT MCVARY, MD,⁴ CG ROEHRBORN, MD,⁴
MF DARSON, MD,⁸ EE ALEXANDER, MD,⁸
RR GONZALEZ, MD,⁸ JC ULCHAKER, MD⁹

IN-OFFICE, FIRST-LINE TREATMENT OPTION


WHAT IS REZŪM®?

- Convective Water Vapor Energy (WAVE®) technology
- Transurethral procedure
- Water vapor contained within zone in which delivered
- Indicated for prostate sizes 30–80 cm³, including median lobe/central zone hyperplasia



WHICH PATIENTS MIGHT BENEFIT?


Based on data from 947 patients, 86% of BPH patients receive Rezūm as a first-line therapy or an alternative to BPH medication.¹




"This minimally invasive procedure warrants consideration as a first-line therapeutic alternative to medical therapy in men seeking treatment for moderate to severe symptoms of BPH including those with median lobe hyperplasia."

– Dr. Claus Roehrborn, UT Southwestern²


FLEXIBILITY TO TREAT ALL AREAS OF ENLARGED TISSUE




2 out of 3 men have a PUA $\geq 35^\circ$ that contributes to LUTS³



In a commercial setting, 54% of patients had a median lobe/enlarged central zone treated during their Rezūm procedure




Patients obtained additional clinically meaningful symptom improvement when the median lobe was treated.



PRE-TREATMENT
52 cm³ prostate




POST-TREATMENT
3Tx/RLL; 4Tx/LLL; 2Tx/ML



DURABLE AND REPEATABLE OUTCOMES

REZŪM PIVOTAL STUDY⁴


- 197 U.S. men randomized to treatment (n=136) or control (n=61)
- Significant relief reflected in IPSS and Qmax outcomes was durable in patients with moderate and severe LUTS
- Low AE and surgical retreatment rate at 3 years; 4 of 6 patients due to untreated median lobe (Figure 1)



Rezūm has the lowest retreatment rates when compared to other minimally invasive BPH treatments at 3 years.

REZŪM POST-MARKET STUDY⁸

- Consecutive cases accrued by multiple community urologists
- 131 patients with moderate-to-severe LUTS included in retrospective analysis
- Urologists used own discretion for patient selection
- IPSS improvements closely replicated across other published studies (Figure 2)
- Preservation of sexual function; no de novo erectile dysfunction reported



IPSS improvement is consistent and durable across all Rezūm studies.